Back
Results - Announcements
Titan Biotech Ltd consolidated sales up 21.18% on year in Q2FY2026, net profit jumped 44.21%
13-Aug-2026, 07:24
Titan Biotech Ltd share price softened by 0.54% to Rs 396.05. The Company's net profit surged by 44.21% to Rs 9.46 crore, while revenue from operations gained significantly 21.18% to Rs 59.17 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.11 lakh crore, climbing 14.40%. It has eased by 0.10% over last one week and advanced by 12.48% in last one month while the market capitalization of Titan Biotech Ltd has slipped by 1.65% and 12.55% in the same period respectively. Profit before tax (PBT) of Titan Biotech Ltd stood at Rs 12.73 crore in Q2 FY26, expanding by 56.97% year-on-year, and rallying 23.83% quarter-on-quarter. EBITDA came in at Rs 11 crore, jumping 33.17% YoY and surging by 40.53% sequentially. Total expenses advancing by 18.88% to Rs 48.05 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.93 crore, going up by 15.52% YoY, while employee benefits expense was at Rs 8.7 crore, contracting 7.84% YoY. For the TTM ended FY26, revenue from operations declined slightly by 4.64% to Rs 156.45 crore, while net profit plunged by 22.78% to Rs 18.27 crore, compared to previous TTM. EBITDA jumped by 3237% to Rs 21.52 crore, and PBT tanked by 22.71% to Rs 24.37 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 20.12 crore in FY26, as against Rs 21.15 crore in FY25. Titan Biotech Ltd rallied 353.30% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.
Titan Biotech Ltd share price softened by 0.54% to Rs 396.05. The Company's net profit surged by 44.21% to Rs 9.46 crore, while revenue from operations gained significantly 21.18% to Rs 59.17 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.11 lakh crore, climbing 14.40%. It has eased by 0.10% over last one week and advanced by 12.48% in last one month while the market capitalization of Titan Biotech Ltd has slipped by 1.65% and 12.55% in the same period respectively. Profit before tax (PBT) of Titan Biotech Ltd stood at Rs 12.73 crore in Q2 FY26, expanding by 56.97% year-on-year, and rallying 23.83% quarter-on-quarter. EBITDA came in at Rs 11 crore, jumping 33.17% YoY and surging by 40.53% sequentially. Total expenses advancing by 18.88% to Rs 48.05 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.93 crore, going up by 15.52% YoY, while employee benefits expense was at Rs 8.7 crore, contracting 7.84% YoY. For the TTM ended FY26, revenue from operations declined slightly by 4.64% to Rs 156.45 crore, while net profit plunged by 22.78% to Rs 18.27 crore, compared to previous TTM. EBITDA jumped by 3237% to Rs 21.52 crore, and PBT tanked by 22.71% to Rs 24.37 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 20.12 crore in FY26, as against Rs 21.15 crore in FY25. Titan Biotech Ltd rallied 353.30% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.